The live attenuated polio vaccine market size has grown strongly in recent years. It will grow from $1.85 billion in 2024 to $2.0 billion in 2025 at a compound annual growth rate (CAGR) of 8.3%. The growth during the historic period can be attributed to mass immunization campaigns, concerns over vaccine-derived poliovirus, government immunization programs, increased public awareness and education, and greater accessibility and affordability of vaccines.
The live attenuated polio vaccine market size is expected to see strong growth in the next few years. It will grow to $2.71 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth during the forecast period can be attributed to improved vaccine stability and shelf life, a resurgence of polio cases in conflict zones, donor fatigue in eradication efforts, the expansion of routine immunization programs, and increased research and development for safer live attenuated vaccine strains. Key trends expected during this period include the emergence of vaccine-derived poliovirus, the development of new oral polio vaccines, technological advancements in vaccine formulations, the integration of digital technologies, and the strengthening of public-private partnerships.
The expansion of immunization programs is expected to significantly contribute to the growth of the live attenuated polio vaccine (LAPV) market in the coming years. Immunization programs are structured efforts by governments, health organizations, and other institutions to distribute vaccines to populations to prevent the spread of infectious diseases. These programs are gaining momentum due to heightened global awareness about the importance of disease prevention, along with strong support from governments, international health organizations, and funding bodies. Immunization programs support LAPVs by ensuring their widespread distribution, safe administration, and high coverage rates, all of which help build herd immunity, prevent virus transmission, and further the goal of global polio eradication. For example, in October 2023, the Centers for Disease Control and Prevention (CDC) reported that global coverage for the first dose of the diphtheria-tetanus-pertussis (DTP) vaccine increased from 86% to 89% between 2021 and 2022. As a result, the expansion of immunization programs is anticipated to drive market growth for live attenuated polio vaccines.
Leading companies in the live attenuated polio vaccine market are focusing on obtaining regulatory approvals to ensure their vaccines meet the necessary safety and efficacy standards set by global health authorities. Regulatory approvals refer to the formal authorization granted by government health agencies or regulatory bodies that permit the marketing, sale, and use of a product, such as a vaccine, within specific regions or countries. For instance, in July 2024, Biological E, an India-based pharmaceutical company, received approval from the World Health Organization (WHO) for its novel oral polio vaccine type 2 (nOPV2). This next-generation, live attenuated oral vaccine is designed to better address the challenges posed by traditional oral polio vaccines, especially in combating circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks. The nOPV2 is engineered for enhanced genetic stability, reducing the risk of the vaccine virus reverting to a virulent form an issue that has been a concern with older vaccines.
In June 2024, SK bioscience, a South Korea-based vaccine and biotechnology company, acquired IDT Biologika for approximately $244 million. This acquisition strengthens SK bioscience’s leadership in vaccine development and manufacturing, expanding its capabilities and service offerings to improve global health outcomes. The acquisition also aligns with SK bioscience’s long-term goals of operational growth and innovation. IDT Biologika, based in Germany, is a contract development and manufacturing organization specializing in viral vaccines, including live attenuated virus vaccines.
Major players in the live attenuated polio vaccine market are Sanofi Pasteur, GlaxoSmithKline plc, LG Chem Ltd., Serum Institute of India Pvt. Ltd., Biological E. Limited, Indian Immunologicals Limited, Sinovac Biotech Ltd., Shenzhen Kangtai Biological Products Co. Ltd., Vabiotech, Emergent BioSolutions Inc., Valneva SE, Bio Farma, PT Bio Farm, Bilthoven Bio, Panacea Biotec, Haffkine Biopharmaceutical, Panacea Biotec Ltd., Zydus Cadila, Liaoning Cheng Da Biotechnology Co.Ltd, Bharat Biotech International Limited.
North America was the largest region in the live attenuated polio vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in live attenuated polio vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the live attenuated polio vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The live attenuated polio vaccine (LAPV) is an oral polio vaccine (OPV) containing a weakened form of the poliovirus. This form stimulates a robust immune response without causing disease in healthy individuals. It mimics natural infection, providing long-lasting immunity and helping to prevent the transmission of the virus within communities.
The main types of vaccines in live attenuated polio vaccines include monovalent, bivalent, and trivalent. A monovalent oral polio vaccine (mOPV) is specifically designed to protect against a single type of poliovirus, such as type 1, type 2, or type 3. It can be administered orally, via intramuscular injection, or subcutaneously, depending on the age group infants (0-1 years), children (1-5 years), and adults (above 5 years). This vaccine is used by various end-users, including hospitals, clinics, public health agencies, and other healthcare providers.
The live attenuated polio vaccine market research report is one of a series of new reports that provides live attenuated polio vaccine market statistics, including live attenuated polio vaccine industry global market size, regional shares, competitors with a live attenuated polio vaccine market share, detailed live attenuated polio vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the live attenuated polio vaccine industry. This live attenuated polio vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The live attenuated polio vaccine market consists of sales of monovalent oral polio vaccine (mOPV), bivalent oral polio vaccine (bOPV), novel oral polio vaccine, and trivalent oral polio vaccine (tOPV). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The live attenuated polio vaccine market size is expected to see strong growth in the next few years. It will grow to $2.71 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth during the forecast period can be attributed to improved vaccine stability and shelf life, a resurgence of polio cases in conflict zones, donor fatigue in eradication efforts, the expansion of routine immunization programs, and increased research and development for safer live attenuated vaccine strains. Key trends expected during this period include the emergence of vaccine-derived poliovirus, the development of new oral polio vaccines, technological advancements in vaccine formulations, the integration of digital technologies, and the strengthening of public-private partnerships.
The expansion of immunization programs is expected to significantly contribute to the growth of the live attenuated polio vaccine (LAPV) market in the coming years. Immunization programs are structured efforts by governments, health organizations, and other institutions to distribute vaccines to populations to prevent the spread of infectious diseases. These programs are gaining momentum due to heightened global awareness about the importance of disease prevention, along with strong support from governments, international health organizations, and funding bodies. Immunization programs support LAPVs by ensuring their widespread distribution, safe administration, and high coverage rates, all of which help build herd immunity, prevent virus transmission, and further the goal of global polio eradication. For example, in October 2023, the Centers for Disease Control and Prevention (CDC) reported that global coverage for the first dose of the diphtheria-tetanus-pertussis (DTP) vaccine increased from 86% to 89% between 2021 and 2022. As a result, the expansion of immunization programs is anticipated to drive market growth for live attenuated polio vaccines.
Leading companies in the live attenuated polio vaccine market are focusing on obtaining regulatory approvals to ensure their vaccines meet the necessary safety and efficacy standards set by global health authorities. Regulatory approvals refer to the formal authorization granted by government health agencies or regulatory bodies that permit the marketing, sale, and use of a product, such as a vaccine, within specific regions or countries. For instance, in July 2024, Biological E, an India-based pharmaceutical company, received approval from the World Health Organization (WHO) for its novel oral polio vaccine type 2 (nOPV2). This next-generation, live attenuated oral vaccine is designed to better address the challenges posed by traditional oral polio vaccines, especially in combating circulating vaccine-derived poliovirus type 2 (cVDPV2) outbreaks. The nOPV2 is engineered for enhanced genetic stability, reducing the risk of the vaccine virus reverting to a virulent form an issue that has been a concern with older vaccines.
In June 2024, SK bioscience, a South Korea-based vaccine and biotechnology company, acquired IDT Biologika for approximately $244 million. This acquisition strengthens SK bioscience’s leadership in vaccine development and manufacturing, expanding its capabilities and service offerings to improve global health outcomes. The acquisition also aligns with SK bioscience’s long-term goals of operational growth and innovation. IDT Biologika, based in Germany, is a contract development and manufacturing organization specializing in viral vaccines, including live attenuated virus vaccines.
Major players in the live attenuated polio vaccine market are Sanofi Pasteur, GlaxoSmithKline plc, LG Chem Ltd., Serum Institute of India Pvt. Ltd., Biological E. Limited, Indian Immunologicals Limited, Sinovac Biotech Ltd., Shenzhen Kangtai Biological Products Co. Ltd., Vabiotech, Emergent BioSolutions Inc., Valneva SE, Bio Farma, PT Bio Farm, Bilthoven Bio, Panacea Biotec, Haffkine Biopharmaceutical, Panacea Biotec Ltd., Zydus Cadila, Liaoning Cheng Da Biotechnology Co.Ltd, Bharat Biotech International Limited.
North America was the largest region in the live attenuated polio vaccine market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in live attenuated polio vaccine report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the live attenuated polio vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The live attenuated polio vaccine (LAPV) is an oral polio vaccine (OPV) containing a weakened form of the poliovirus. This form stimulates a robust immune response without causing disease in healthy individuals. It mimics natural infection, providing long-lasting immunity and helping to prevent the transmission of the virus within communities.
The main types of vaccines in live attenuated polio vaccines include monovalent, bivalent, and trivalent. A monovalent oral polio vaccine (mOPV) is specifically designed to protect against a single type of poliovirus, such as type 1, type 2, or type 3. It can be administered orally, via intramuscular injection, or subcutaneously, depending on the age group infants (0-1 years), children (1-5 years), and adults (above 5 years). This vaccine is used by various end-users, including hospitals, clinics, public health agencies, and other healthcare providers.
The live attenuated polio vaccine market research report is one of a series of new reports that provides live attenuated polio vaccine market statistics, including live attenuated polio vaccine industry global market size, regional shares, competitors with a live attenuated polio vaccine market share, detailed live attenuated polio vaccine market segments, market trends and opportunities, and any further data you may need to thrive in the live attenuated polio vaccine industry. This live attenuated polio vaccine market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The live attenuated polio vaccine market consists of sales of monovalent oral polio vaccine (mOPV), bivalent oral polio vaccine (bOPV), novel oral polio vaccine, and trivalent oral polio vaccine (tOPV). Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Live Attenuated Polio Vaccine Market Characteristics3. Live Attenuated Polio Vaccine Market Trends And Strategies4. Live Attenuated Polio Vaccine Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market32. Global Live Attenuated Polio Vaccine Market Competitive Benchmarking And Dashboard33. Key Mergers And Acquisitions In The Live Attenuated Polio Vaccine Market34. Recent Developments In The Live Attenuated Polio Vaccine Market
5. Global Live Attenuated Polio Vaccine Growth Analysis And Strategic Analysis Framework
6. Live Attenuated Polio Vaccine Market Segmentation
7. Live Attenuated Polio Vaccine Market Regional And Country Analysis
8. Asia-Pacific Live Attenuated Polio Vaccine Market
9. China Live Attenuated Polio Vaccine Market
10. India Live Attenuated Polio Vaccine Market
11. Japan Live Attenuated Polio Vaccine Market
12. Australia Live Attenuated Polio Vaccine Market
13. Indonesia Live Attenuated Polio Vaccine Market
14. South Korea Live Attenuated Polio Vaccine Market
15. Western Europe Live Attenuated Polio Vaccine Market
16. UK Live Attenuated Polio Vaccine Market
17. Germany Live Attenuated Polio Vaccine Market
18. France Live Attenuated Polio Vaccine Market
19. Italy Live Attenuated Polio Vaccine Market
20. Spain Live Attenuated Polio Vaccine Market
21. Eastern Europe Live Attenuated Polio Vaccine Market
22. Russia Live Attenuated Polio Vaccine Market
23. North America Live Attenuated Polio Vaccine Market
24. USA Live Attenuated Polio Vaccine Market
25. Canada Live Attenuated Polio Vaccine Market
26. South America Live Attenuated Polio Vaccine Market
27. Brazil Live Attenuated Polio Vaccine Market
28. Middle East Live Attenuated Polio Vaccine Market
29. Africa Live Attenuated Polio Vaccine Market
30. Live Attenuated Polio Vaccine Market Competitive Landscape And Company Profiles
31. Live Attenuated Polio Vaccine Market Other Major And Innovative Companies
35. Live Attenuated Polio Vaccine Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Live Attenuated Polio Vaccine Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on live attenuated polio vaccine market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for live attenuated polio vaccine ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The live attenuated polio vaccine market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Vaccine Type: Monovalent; Bivalent; Trivalent2) By Administration Route: Oral Administration; Intramuscular Injection; Subcutaneous Injection
3) By Age Group: Infants (0-1 years); Children (1-5 years); Adults (Above 5 years)
4) By End-User: Hospitals; Clinics; Public Health Agencies; Other End-Users
Subsegments:
1) Monovalent: mOPV1 For Serotype 12) Bivalent: Type 1; Type 3
3) Trivalent: Poliovirus Type 1; Poliovirus Type 2; Poliovirus Type 3
Key Companies Profiled: Sanofi Pasteur; GlaxoSmithKline plc; LG Chem Ltd.; Serum Institute of India Pvt. Ltd.; Biological E. Limited
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Sanofi Pasteur
- GlaxoSmithKline plc
- LG Chem Ltd.
- Serum Institute of India Pvt. Ltd.
- Biological E. Limited
- Indian Immunologicals Limited
- Sinovac Biotech Ltd.
- Shenzhen Kangtai Biological Products Co. Ltd.
- Vabiotech
- Emergent BioSolutions Inc.
- Valneva SE
- Bio Farma
- PT Bio Farm
- Bilthoven Bio
- Panacea Biotec
- Haffkine Biopharmaceutical
- Panacea Biotec Ltd.
- Zydus Cadila
- Liaoning Cheng Da Biotechnology Co.Ltd
- Bharat Biotech International Limited